What Researchers Did
This paper examined the challenges facing hyperbaric medicine, including the loss of access to approved uses and the issue of overutilization.
What They Found
The author observed a significant reduction in the availability of hyperbaric oxygen therapy (HBOT) for many Federal Drug Administration-approved conditions. They also identified overutilization stemming from weakened practice standards and issues with reimbursement processes. The paper suggests restoring broader availability and ensuring HBOT is used only when medically necessary, following principles of the right indication for the right patient at the right time and duration.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
As an invited commentary, this paper presents an expert opinion and does not include new research data or empirical findings.